OctoPlus’ origins date back to 1995, when the company was founded by two pharmacists: Dr. Joost Holthuis, who started OctoPlus after several years at US Biotech company Cetus and Prof. dr. Daan Crommelin, professor at Utrecht University in The Netherlands and world-renown expert in liposomes. Operations started in an incubator facility on the bioscience park in Leiden, one of the first life science parks in the Netherlands. The company’s focus was entirely on providing pharmaceutical formulation services in the first years.
Over time, activities started to focus more and more on complex injectables and from the year 2000 onwards, the company moved to its own facility. OctoPlus started to develop its own drug delivery technologies, mostly in the area of depot injections based on polymers. OctoPlus brought several innovative products to clinical trials, for example in the area of siRNA. Over the years, the company worked on over 50 products, from their own pipeline and mostly from partners .
Since 2013, OctoPlus is part of Dr. Reddy’s one of the world’s leading generic companies. Dr. Reddy’s mission is to accelerate access to affordable medicines and finding solutions for unmet needs. Good Health Can’t Wait. Click here to learn about our link to Dr. Reddy’s.
OctoPlus is a specialty pharmaceutical company globally renowned for its expertise in pharmaceutical development of injectables and is based on the bioscience park, one of the leading bioscience industry parks in Europe. The company employs around 120 people, and is highly culturally diverse, with over 20 different nationalities represented in its workforce.
Our core business is formulation & process development of complex injectables
We believe that our expertise in development of complex injectables products and our proprietary controlled release technology platform can be maximized through:
- Research collaborations
- Co-development partnerships
We are actively looking for collaborations with universities and industry to develop new products and technologies from concept to market.